Following successful development of CAR-T therapies targeting CD19 for refractory non-Hodgkin’s B-cell lymphoma (B-NHL) and B-cell acute lymphoblastic leukaemia (B-ALL), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA) in MM was developed [47,48]. This evidence concerns the gene TNFRSF17 and acute lymphoblastic leukemia.